Godhania Udai, Rajendran Jayaprakash, Odeyemi Oluwagbenga
Psychiatry, Priory Hospital, Birmingham, GBR.
Cureus. 2024 Nov 8;16(11):e73269. doi: 10.7759/cureus.73269. eCollection 2024 Nov.
We report the case of a 23-year-old man who developed orofacial dyskinesia secondary to aripiprazole whilst being treated for psychosis in the hospital. He was known to mental health services and had suffered a relapse of bipolar affective disorder. Upon cessation of aripiprazole and commencement of quetiapine, there was a rapid reversal of his movement disorder. He also did not have any notable risk factors associated with developing orofacial dyskinesia beyond having an affective disorder, which highlights the unusual and rare occurrence of this side effect with the use of aripiprazole. Unlike many first-generation antipsychotics, aripiprazole had been previously reported to be protective against and also treat extrapyramidal side effects (EPSE) due to its mixed mechanism of action, which includes being a partial dopamine receptor 2 (DR2) agonist.
我们报告了一例23岁男性患者的病例，该患者在医院接受精神病治疗期间因阿立哌唑出现口面部运动障碍。他为精神卫生服务机构的已知病例，患有双相情感障碍复发。停用阿立哌唑并开始使用喹硫平后，他的运动障碍迅速逆转。除了患有情感障碍外，他没有任何与口面部运动障碍相关的显著风险因素，这凸显了使用阿立哌唑出现这种副作用的不寻常和罕见情况。与许多第一代抗精神病药物不同，阿立哌唑此前曾被报道因其混合作用机制（包括作为部分多巴胺受体2（DR2）激动剂）而对锥体外系副作用（EPSE）具有预防和治疗作用。
